New lung cancer diagnoses and deaths have decreased as a result of reduced smoking and advances in early screening and treatment. However, lung cancer remains the leading cause of cancer deaths, accountingRead More…
PROTACs, also named as Proteolysis-Targeting Chimeras, is a new type of drug that is different from antibodies and traditional small molecular inhibitors. It consists of target proteins ligand, linker, and E3 ubiquitinRead More…
PROTAC is a novel technique that induces targeted protein degradation by the ubiquitin-proteasome system (UPS). Different from the traditional occupation-driven pharmacological principles, event-driven PROTAC technology has many advantages, such as high activity,Read More…